Web Exclusives
Learn about the top issues facing ANA member nurses, how ANA is working for you, and what ANA is doing to advance nursing.
June 2018 Vol. 13 No. 6
Click here to access the digital edition When you take care of yourself, you’re better able to take care of your patients and their…
Dopamine and family history of alcohol use disorder
People with a family history of alcohol use disorder (AUD) release more dopamine in the brain’s main reward center in response to the expectation…
FDA approves new drug for thrombocytopenia in patients with chronic liver disease
On May 21, the U.S. Food and Drug Administration (FDA) approved approved Doptelet (avatrombopag) tablets to treat thrombocytopenia in adults with chronic liver disease…
Depression increases risk of cognitive decline
A study in Psychological Medicine reports that depression leads to greater cognitive decline in older adults. (more…)
FDA expands use of Gilenya to pediatric patients with MS
On May 11, the U.S. Food and Drug Administration (FDA) approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age…
FDA approves first epoetin alfa biosimilar
On May 15, the U.S. Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment…
Nurses remain woefully underrepresented in news stories
The classic 1997 Woodhull Study on Nursing and the Media found that nurses were identified as sources in only 4% of quotations or other…
Large-scale vaccination for Ebola virus: Will it work?
A study in Frontiers in Immunology reports that the vaccination rate needed to establish group immunity (80%) to the Ebola virus isn’t realistic and…
New endoscopic device for controlling GI bleeding
On May 7, the U.S. Food and Drug Administration (FDA) permitted marketing of Hemospray, a new device used to help control certain types of…
Tracking nursing student errors
Safe Student Reports is a free tool for tracking nursing student errors and near misses. (more…)
June ANA on the Frontline: 2017 Annual Report
Learn about the top issues facing ANA member nurses, how ANA is working for you, and what ANA is doing to advance…
June 2018 Vol. 13 No. 6
Click here to access the digital edition When you take care of yourself, you’re better able to take care of your patients…
Dopamine and family history of alcohol use disorder
People with a family history of alcohol use disorder (AUD) release more dopamine in the brain’s main reward center in response to…
FDA approves new drug for thrombocytopenia in patients with chronic liver disease
On May 21, the U.S. Food and Drug Administration (FDA) approved approved Doptelet (avatrombopag) tablets to treat thrombocytopenia in adults with chronic…
Depression increases risk of cognitive decline
A study in Psychological Medicine reports that depression leads to greater cognitive decline in older adults. (more…)
FDA expands use of Gilenya to pediatric patients with MS
On May 11, the U.S. Food and Drug Administration (FDA) approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and…
FDA approves first epoetin alfa biosimilar
On May 15, the U.S. Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for…
Nurses remain woefully underrepresented in news stories
The classic 1997 Woodhull Study on Nursing and the Media found that nurses were identified as sources in only 4% of quotations…
Large-scale vaccination for Ebola virus: Will it work?
A study in Frontiers in Immunology reports that the vaccination rate needed to establish group immunity (80%) to the Ebola virus isn’t…
New endoscopic device for controlling GI bleeding
On May 7, the U.S. Food and Drug Administration (FDA) permitted marketing of Hemospray, a new device used to help control certain…
Tracking nursing student errors
Safe Student Reports is a free tool for tracking nursing student errors and near misses. (more…)
Poll




NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.










